LERONLIMAB

UNII:	Y1J4NP8FF0
Formula:
Preferred Substance Name:	LERONLIMAB

674782-26-4
IMMUNOGLOBULIN G4, ANTI-(HUMAN CHEMOKINE RECEPTOR CCR5) (HUMANIZED MONOCLONAL PRO 140 .GAMMA.4-CHAIN), DISULFIDE WITH HUMANIZED MONOCLONAL PRO 140 .KAPPA.-CHAIN, DIMER
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS C-C CHEMOKINE RECEPTOR TYPE 5 (CCR5, ANTIGEN CD195))HUMANIZED MONOCLONAL ANTIBODY.GAMMA.4 HEAVY CHAIN (1-449) (HUMANIZED VH (HOMO SAPIENS IGHV3-15*06 (72%) (IGHD)-IGHJ5*01 (87%)) (8.8.15) (1-122) -HOMO SAPIENS IGHG4*01 (123-449)) (136-219')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-219') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV2D-29*02 (87%) IGKJ1*01)(11.3.9) (1'-112') -HOMO SAPIENS IGKC*01 (113'-219')), DIMER (228-228'':231-231'')-BISDISULFIDE
LERONLIMAB [INN]
LERONLIMAB [USAN]
LERONLIMAB [WHO-DD]
PRO140
PRO-140

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

LERONLIMAB

Synonyms and Mappings

Resources